NASDAQ:OVID
Ovid Therapeutics Inc Stock News
$3.06
-0.0100 (-0.326%)
At Close: May 03, 2024
Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:05am, Friday, 26'th Apr 2024
Ovid Therapeutics (OVID) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
08:00am, Thursday, 04'th Apr 2024
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
08:00am, Wednesday, 28'th Feb 2024
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
08:00am, Tuesday, 06'th Feb 2024
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of
NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
01:33pm, Thursday, 09'th Nov 2023
Ovid Therapeutics (OVID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
07:30am, Wednesday, 20'th Sep 2023
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and
3 Very Promising Penny Stocks That Are Flying Under the Radar
09:38pm, Tuesday, 15'th Aug 2023
Warning: while this discussion obviously centers on penny stocks to buy, this subsegment of the market carries astounding risks. While it's difficult to verify, one source has the failure rate of thes
Ovid Therapeutics (OVID) Reports Q2 Loss, Lags Revenue Estimates
10:32am, Friday, 04'th Aug 2023
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.21 per share a year ago.
Ovid Therapeutics: Bullish Outlook Strengthened By Positive 2-Year Open-Label Trial Results
02:12am, Tuesday, 13'th Jun 2023
Ovid Therapeutics' TAK-935 has a high potential for positive Phase 3 clinical trial results for both Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS). Significant Revenue Potential. The median a
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
09:54am, Friday, 05'th May 2023
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.23 per share a year ago.
Ovid Therapeutics (OVID) Upgraded to Buy: Here's What You Should Know
01:42pm, Wednesday, 12'th Apr 2023
Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
08:00am, Monday, 10'th Apr 2023
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies a
Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
08:00am, Thursday, 09'th Mar 2023
NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o
Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)
10:00am, Friday, 02'nd Dec 2022
NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of
